Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03205176 · ClinicalTrials.gov registry record · Phase 1
AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 49
- Enrollment target
NCT03205176 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 49 participants.
The verdict
NCT03205176, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 49 participants
- Enrollment target
Study Summary
This is a first-time-in-man (FTIM) multicenter, dose escalation study designed to investigate the safety, pharmacokinetics, and pharmacodynamics of AZD5153 in patients with malignant solid tumors, including lymphomas.
Interventions
- DRUG Olaparib
- DRUG AZD5153
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2017-06-30 |
| Est. Completion | 2021-04-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03205176
The ClinicalTrials.gov registry entry for NCT03205176 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Olaparib is the first listed.
NCT03205176 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03205176 about?
NCT03205176 is a clinical study titled "AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas". This is a first-time-in-man (FTIM) multicenter, dose escalation study designed to investigate the safety, pharmacokinetics, and pharmacodynamics of AZD5153 in patients with malignant solid tumors, including lymphomas.
What is the current status of trial NCT03205176?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 49 participants. The study started on 2017-06-30. Estimated completion is 2021-04-08.
What interventions are being tested in trial NCT03205176?
The interventions under investigation include: Olaparib (DRUG), AZD5153 (DRUG).
Who is sponsoring clinical trial NCT03205176?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.